CAMBRIDGE, England & BOSTON — December 16, 2025 — Bicycle Therapeutics plc, a clinical-stage pharmaceutical company pioneering bicyclic peptide–based therapeutics, announced the establishment of multiple long-term strategic partnerships to create an end-to-end supply chain supporting its wholly owned radiopharmaceutical pipeline. Central to the initiative is a 15-year contract with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400 tonnes of reprocessed uranium (RepU), forming the foundation of a vertically integrated ecosystem to enable the discovery, development, and future commercial supply of 212Pb-based Bicycle® Radioconjugates (BRC®).
Science Significance
The announcement represents a major scientific advance in the rapidly evolving field of Targeted Alpha Therapy (TAT). 212Pb (lead-212) is a highly potent alpha-emitting radioisotope capable of delivering precise, high-energy radiation directly to cancer cells while limiting off-target toxicity. Bicycle’s partnerships enable the extraction of 228Th from RepU, followed by processing into 224Ra and incorporation into a bespoke 212Pb generator. By pairing its proprietary Bicycle® targeting technology with a reliable isotope supply, the company is positioning itself to generate next-generation radioconjugates with high specificity, scalability, and therapeutic impact against solid tumors.
Regulatory Significance
Radiopharmaceutical development requires strict alignment with GMP manufacturing, radioactive materials regulation, and cross-jurisdictional oversight. The long-term agreements with the NDA, the United Kingdom National Nuclear Laboratory (UKNNL), and SpectronRx demonstrate regulatory foresight by addressing one of the most complex compliance challenges in radiopharma: secure, traceable isotope sourcing and processing. Establishing a compliant upstream supply chain early reduces regulatory risk as Bicycle advances its BRC® programs toward clinical trials and eventual commercialization, reinforcing readiness for FDA, EMA, and UK regulatory review.
Business Significance
Advertisement
From a business perspective, the creation of a fully integrated, long-duration radiopharmaceutical supply chain is a significant competitive differentiator. Isotope scarcity has historically constrained the growth of the radiopharmaceutical sector. By securing access to RepU for up to 15 years, Bicycle mitigates supply volatility while enabling the potential production of tens of thousands of 212Pb doses annually. The collaboration with SpectronRx to develop a bespoke, wholly owned 212Pb generator further strengthens control over cost, quality, and scalability, positioning Bicycle to capture long-term value across discovery, development, and commercial stages.
Patients’ Significance
For patients with hard-to-treat cancers, the announcement signals progress toward more precise and potent treatment options. Bicycle’s BRC® platform aims to deliver high-energy alpha radiation directly to tumor cells, potentially improving efficacy while minimizing systemic toxicity. Reliable isotope availability is essential to ensuring consistent patient access once therapies reach the clinic. By addressing supply challenges at an early stage, Bicycle increases the likelihood that future radiopharmaceutical treatments can be delivered at scale, on schedule, and with consistent quality, directly benefiting patients who depend on advanced oncology therapies.
Policy Significance
At a policy level, the initiative highlights how life sciences innovation can intersect with national nuclear stewardship to generate public health value. The agreement with the NDA demonstrates how reprocessed nuclear materials can be responsibly repurposed for medical innovation, aligning public assets with healthcare advancement. The collaboration reflects growing governmental support for radiopharmaceutical development as a strategic priority, reinforcing the importance of regulatory frameworks that enable safe, ethical, and productive use of nuclear resources in medicine.
Bicycle Therapeutics’ establishment of an end-to-end 212Pb radiopharmaceutical supply chain marks a defining milestone in its evolution as a radiopharma innovator. By combining long-term isotope access, specialized nuclear expertise, and proprietary targeting technology, the company is building the infrastructure required to support GMP-compliant development and future commercialization. For the cGxP.wire audience, the announcement underscores how supply-chain discipline, regulatory preparedness, and scientific ambition must converge to unlock the full potential of next-generation radiopharmaceuticals.
Source: Bicycle Therapeutics plc press release
